Fytexia SAS

Fytexia SAS is a French company dedicated to developing active ingredients for dietary supplements, focusing on health solutions backed by scientific research. Founded in 2003, Fytexia SAS specializes in creating active ingredients for dietary supplements, helping manufacturers enhance their product offerings. The company is headquartered in France and was acquired by ABF Ingredients Limited on February 1, 2022, from ArchiMed, which achieved a 4x multiple on its investment. Matthieu Arguillère remains as CEO of Fytexia SAS post-acquisition.

Fytexia specializes in the development of scientifically-supported active ingredients specifically designed for dietary supplements. The company’s core offerings include a range of functional ingredients targeting various health areas such as metabolism, body composition, and digestive comfort. Their product line features trademarked solutions like Benegut® for digestive health, Bluenesse® for stress relief, and Sinetrol® aimed at facilitating long-term fat loss. These ingredients are marketed primarily to B2B clients, including manufacturers and brands within the food and dietary supplement sectors.

Fytexia’s products are distributed across Europe, North America, and Asia, catering to a diverse clientele comprised of food and supplement professionals looking for natural and scientifically validated solutions to enhance the health and well-being of their end consumers. In the most recent fiscal year of 2023, Fytexia reported a revenue of USD 9. 90 mn and an EBITDA of USD 1. 62 mn.

The company's revenue is generated through B2B transactions with clients in the dietary supplement and food industries, allowing access to proprietary formulations while benefiting from scientific backing. Fytexia plans to expand its product offerings by developing new active ingredients with specific health benefits, though specific launch dates have not been disclosed. The company aims to deepen its market penetration in Europe, North America, and Asia by enhancing its distribution capabilities. The recent acquisition by ABF Ingredients Limited in February 2022 is expected to support these growth initiatives, allowing Fytexia to leverage increased resources and expertise in the pharmaceutical and food market industries.